Company: PFSA
Filing Date: 2025-05-13
Form Type: S-4/A
Source: 0001213900-25-042224
Chunk: 323

Company: Profusa, Inc.
Filing Date: 2025-05-13
Form: S-4/A
Chunk 323
---
 of Profusa and its products; •the historical and current information concerning Profusa’s business, including its financial performance and condition, operations, management and pre -clinicaland clinical data; •the competitive nature of the industry in which Profusa operates; •the Profusa board of directors’ fiduciary duties to Profusa’s stockholders; •the board’s belief that this transaction provides a viable public listing strategy, and addresses the risk of the lack of an available market for an initial public offering at a later date; •the expected cash resources of the combined organization (including the ability to support the combined company’s current and planned operations); •the terms and conditions of the Merger Agreement; •certain shares of New Profusa Common Stock issued to Profusa’s stockholders will be registered on a Form S -4registration statement and will become freely tradable for Profusa’s stockholders who are not affiliates of Profusa and subject to any applicable lock -upagreements; and •the likelihood that the merger will be consummated on a timely basis. The Profusa board of directors also considered a number of uncertainties and risks in its deliberations concerning the merger and the other transactions contemplated by the Merger Agreement, including the following: •the possibility that the merger might not be completed in a timely manner or at all, and the potential adverse effect of the public announcement of the merger on the reputation of Profusa and the ability of Profusa to obtain financing in the future in the event the merger is not completed; •the costs involved in connection with completing the merger, the time and effort of Profusa senior management required to complete the merger, the related disruptions or potential disruptions to Profusa’s business operations and future prospects, including its relationships with its employees, suppliers and partners and others that do business or may do business in the future with Profusa, and related administrative challenges associated with combining the companies; •the additional expenses and obligations to which Profusa’s business will be subject following the merger that Profusa has not previously been subject to, and the operational changes to Profusa’s business, in each case that may result from being a public company; •the fact that the representations and warranties in the Merger Agreement do not survive the closing of the merger and the potential risk of liabilities that may arise post -closing; and •various other risks associated with the combined organization and the merger, including the risks described in the section entitled “ Risk Factors” in this proxy statement/prospectus. The foregoing information is not intended to